Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and have supplanted FU/LV as the standard systemic approach for metastatic colorectal cancer. The recent availability of five a...
Saved in:
Published in | Journal of clinical oncology Vol. 23; no. 20; pp. 4553 - 4560 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
American Society of Clinical Oncology
10.07.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and have supplanted FU/LV as the standard systemic approach for metastatic colorectal cancer. The recent availability of five active chemotherapeutic agents has doubled the median overall survival for metastatic colorectal cancer from 10 to 20 months, and though the optimal strategy for incorporation of all drugs is still unclear, current data support the use of chemotherapy doublets in first-line rather than sequential single-agent therapy. Multidrug regimens increase both response rate and the proportion of patients able to undergo potentially curative resection. In addition, as many as 20% to 30% of patients never receive second-line chemotherapy. When used as single agents, bolus and infusional FU/LV and capecitabine are similarly effective but have differing toxicity. Chemotherapy combinations that incorporate infusion of FU are less toxic and more effective than those using bolus FU dosing. Capecitabine is under study as an alternative dosing method for use in combination regimens; however, the optimal dose has not been defined and final safety and efficacy outcomes are being addressed in ongoing phase II and III investigations. Three combinations have shown excellent first-line efficacy in phase III trials--IFL with bevacizumab, FOLFOX, and FOLFIRI--but neither of these combinations is clearly superior. Sound clinical judgment must continue to guide treatment decisions while we await data regarding the optimal combination and sequence of fluorouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab. |
---|---|
AbstractList | Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and have supplanted FU/LV as the standard systemic approach for metastatic colorectal cancer. The recent availability of five active chemotherapeutic agents has doubled the median overall survival for metastatic colorectal cancer from 10 to 20 months, and though the optimal strategy for incorporation of all drugs is still unclear, current data support the use of chemotherapy doublets in first-line rather than sequential single-agent therapy. Multidrug regimens increase both response rate and the proportion of patients able to undergo potentially curative resection. In addition, as many as 20% to 30% of patients never receive second-line chemotherapy. When used as single agents, bolus and infusional FU/LV and capecitabine are similarly effective but have differing toxicity. Chemotherapy combinations that incorporate infusion of FU are less toxic and more effective than those using bolus FU dosing. Capecitabine is under study as an alternative dosing method for use in combination regimens; however, the optimal dose has not been defined and final safety and efficacy outcomes are being addressed in ongoing phase II and III investigations. Three combinations have shown excellent first-line efficacy in phase III trials--IFL with bevacizumab, FOLFOX, and FOLFIRI--but neither of these combinations is clearly superior. Sound clinical judgment must continue to guide treatment decisions while we await data regarding the optimal combination and sequence of fluorouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab. |
Author | Hanna Kelly Richard M. Goldberg |
Author_xml | – sequence: 1 givenname: Hanna surname: Kelly fullname: Kelly, Hanna organization: Division of Hematology and Oncology, University of North Carolina, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599, USA – sequence: 2 givenname: Richard M surname: Goldberg fullname: Goldberg, Richard M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16002847$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkDlPwzAAhS1URA-Y2VA2FpL6iOOYDUXlUlEHisRmOY5NU-WS7YL673HVCqYnPX3vDd8UjLq-0wBcI5ggDOH8tVglIWmCWMJSfgYmiGIWM0bpCEwgIzhGOfkcg6lzWwhRmhN6AcYogxDnKZuA9fveed3WKlpvtJXDPjK9jd60l85LH-qib3qrlZdNVMhOaXsfFTtrdeej1eDrvnN3f8Xiu650YC7BuZGN01ennIGPx8W6eI6Xq6eX4mEZK8KJj3VOlVFSco455VpiwzEktMp4ingJM1NmkDPFcAqlViZHlMuUSVVChvO8QmQG5sdfZXvnrDZisHUr7V4gKA5-RPAjDn4EYiL4CYub42LYla2u_vmTkADcHoFN_bX5qa0WrpVNE3AstqrHJNyJlFJCfgGhoW_g |
CitedBy_id | crossref_primary_10_1157_13115742 crossref_primary_10_1038_sj_bjc_6603496 crossref_primary_10_1016_j_ejso_2013_11_025 crossref_primary_10_1177_1049909108330026 crossref_primary_10_1007_s00280_009_1186_3 crossref_primary_10_1016_j_radonc_2010_05_021 crossref_primary_10_1002_cncr_25277 crossref_primary_10_1007_BF03256395 crossref_primary_10_1016_j_clinthera_2012_05_001 crossref_primary_10_1016_j_clinre_2015_09_004 crossref_primary_10_1007_s00117_020_00660_y crossref_primary_10_1007_s00384_008_0504_2 crossref_primary_10_1158_1078_0432_CCR_10_2169 crossref_primary_10_3389_fphar_2017_00607 crossref_primary_10_2147_OTT_S266549 crossref_primary_10_1158_1078_0432_CCR_08_0832 crossref_primary_10_1517_17425247_2011_574125 crossref_primary_10_1093_jnci_djp328 crossref_primary_10_1002_cncr_30181 crossref_primary_10_1038_sj_bjc_6604691 crossref_primary_10_1186_s12885_018_4380_z crossref_primary_10_1002_jso_23422 crossref_primary_10_1016_j_ejso_2008_03_010 crossref_primary_10_1179_joc_2007_19_5_590 crossref_primary_10_1245_s10434_006_9112_y crossref_primary_10_1016_j_clinthera_2007_10_013 crossref_primary_10_1097_COC_0b013e318134ee9c crossref_primary_10_17795_jjnpp_30674 crossref_primary_10_3389_fphar_2021_760280 crossref_primary_10_1186_s12957_016_1002_6 crossref_primary_10_1155_2012_196173 crossref_primary_10_1200_JCO_2006_08_1935 crossref_primary_10_2146_ajhp130143 crossref_primary_10_3390_cancers16010205 crossref_primary_10_1007_s00280_010_1368_z crossref_primary_10_1016_j_clcc_2012_05_004 crossref_primary_10_1556_MOnkol_53_2009_2_1 crossref_primary_10_3816_CCC_2007_n_039 crossref_primary_10_1002_cncr_23409 crossref_primary_10_1007_s12032_009_9374_x crossref_primary_10_3816_CCC_2007_n_033 crossref_primary_10_1007_s10147_008_0766_2 crossref_primary_10_3816_CCC_2007_n_032 crossref_primary_10_1016_j_dld_2006_01_016 crossref_primary_10_1186_s12935_019_0837_7 crossref_primary_10_1200_JCO_2006_10_4323 crossref_primary_10_1517_14656566_9_15_2583 crossref_primary_10_1097_RLI_0b013e3182a6094e crossref_primary_10_1111_j_1463_1318_2009_01911_x crossref_primary_10_4143_crt_2010_42_4_185 crossref_primary_10_1007_s00280_009_1018_5 crossref_primary_10_1016_j_critrevonc_2012_06_001 crossref_primary_10_1517_14656566_2011_590132 crossref_primary_10_1093_annonc_mdl386 crossref_primary_10_1007_s00280_010_1266_4 crossref_primary_10_1111_j_1445_2197_2006_03675_x crossref_primary_10_1345_aph_1H492 crossref_primary_10_1002_jcb_29116 crossref_primary_10_1634_theoncologist_2008_0167 crossref_primary_10_1007_s10637_015_0251_5 crossref_primary_10_1002_cncr_26614 crossref_primary_10_1016_j_ejca_2020_05_018 crossref_primary_10_1177_030089160609200504 crossref_primary_10_1016_j_ejca_2014_09_015 crossref_primary_10_3393_jksc_2008_24_3_184 crossref_primary_10_3919_jjsa_68_938 crossref_primary_10_1097_COC_0000000000000045 crossref_primary_10_5937_mp73_34773 crossref_primary_10_1016_S0889_8588_07_80005_0 crossref_primary_10_3892_ol_2011_260 crossref_primary_10_1007_s12029_017_0027_6 crossref_primary_10_3816_CCC_2006_n_013 crossref_primary_10_1007_s00595_007_3592_7 crossref_primary_10_1016_j_currproblcancer_2009_06_004 crossref_primary_10_1016_j_canlet_2006_11_008 crossref_primary_10_1016_j_nucmedbio_2006_01_009 crossref_primary_10_2169_naika_96_441 crossref_primary_10_2217_crc_12_36 crossref_primary_10_18632_oncotarget_24735 crossref_primary_10_1111_j_1477_2574_2012_00558_x crossref_primary_10_1245_s10434_008_0127_4 crossref_primary_10_1007_s00117_020_00661_x crossref_primary_10_1016_j_molstruc_2018_06_006 crossref_primary_10_1002_ijc_32055 crossref_primary_10_1053_j_scrs_2008_09_006 crossref_primary_10_1586_14737140_6_5_801 crossref_primary_10_1038_s41598_020_69230_5 crossref_primary_10_1208_s12249_016_0578_z crossref_primary_10_1200_JCO_2006_06_8353 crossref_primary_10_1007_s11812_006_0002_9 crossref_primary_10_18632_oncotarget_6241 crossref_primary_10_2165_00148581_200810030_00006 crossref_primary_10_1007_s00270_007_9189_0 crossref_primary_10_1007_s12029_017_0017_8 crossref_primary_10_1016_j_clinthera_2006_11_015 crossref_primary_10_3816_CLC_2008_n_041 crossref_primary_10_3390_curroncol29090489 crossref_primary_10_1007_s00261_020_02766_2 crossref_primary_10_1158_1078_0432_CCR_05_2788 crossref_primary_10_1016_j_canlet_2009_01_026 crossref_primary_10_1097_MD_0000000000003652 crossref_primary_10_1158_1078_0432_CCR_12_1800 crossref_primary_10_1016_S1579_2129_08_60015_4 crossref_primary_10_1016_j_ejpb_2015_06_014 crossref_primary_10_1016_j_suronc_2007_08_010 crossref_primary_10_1016_j_soncn_2006_08_003 crossref_primary_10_1016_j_ejso_2008_06_189 crossref_primary_10_1016_j_tranon_2023_101617 crossref_primary_10_1016_j_soncn_2006_08_002 crossref_primary_10_1016_j_soncn_2006_08_001 crossref_primary_10_1016_j_critrevonc_2009_02_006 crossref_primary_10_1177_030089160709300617 crossref_primary_10_21294_1814_4861_2018_17_3_34_40 crossref_primary_10_1007_s12012_019_09541_w crossref_primary_10_1016_j_jconrel_2014_08_030 crossref_primary_10_1111_ajco_12456 crossref_primary_10_1038_ncponc1303 crossref_primary_10_1111_j_1463_1318_2007_01376_x crossref_primary_10_1634_theoncologist_12_1_38 crossref_primary_10_1007_s00280_008_0797_4 crossref_primary_10_1007_s00268_008_9817_0 crossref_primary_10_1093_jn_nxz029 crossref_primary_10_1097_PPO_0b013e3181e07690 crossref_primary_10_1007_s12094_010_0551_3 crossref_primary_10_1093_annonc_mdl174 crossref_primary_10_1007_s10637_010_9484_5 crossref_primary_10_1371_journal_pone_0027086 crossref_primary_10_1016_j_jinorgbio_2008_10_013 crossref_primary_10_1097_01_NAJ_0000301017_26500_db crossref_primary_10_1093_ejcts_ezx020 crossref_primary_10_1007_s10147_010_0045_x crossref_primary_10_20964_2017_08_78 crossref_primary_10_1586_14737167_2015_982100 crossref_primary_10_1002_1878_0261_12965 crossref_primary_10_1186_1756_0500_5_314 crossref_primary_10_1021_bc900513u crossref_primary_10_1158_1078_0432_CCR_08_0761 crossref_primary_10_1371_journal_pone_0139940 crossref_primary_10_1038_sj_tpj_6500463 crossref_primary_10_2217_14796694_3_2_141 crossref_primary_10_2217_pgs_2016_0102 crossref_primary_10_1002_jso_23394 crossref_primary_10_1017_S1460396921000303 crossref_primary_10_9738_INTSURG_D_12_00020_1 crossref_primary_10_1038_s41416_023_02155_8 crossref_primary_10_1007_s12032_011_9839_6 crossref_primary_10_1038_nrclinonc_2009_128 crossref_primary_10_1080_02841860701261568 crossref_primary_10_2217_pgs_12_95 crossref_primary_10_18632_oncotarget_7812 crossref_primary_10_2147_OTT_S284211 crossref_primary_10_3111_13696998_2011_556693 crossref_primary_10_1016_j_clon_2007_08_002 crossref_primary_10_1111_cas_12224 crossref_primary_10_1016_S0001_7310_06_73376_2 crossref_primary_10_1200_JCO_2006_10_1220 crossref_primary_10_1016_j_jvir_2006_11_003 crossref_primary_10_1097_COC_0b013e31826e0703 crossref_primary_10_1007_s00384_010_0996_4 crossref_primary_10_1586_14737140_6_10_1385 crossref_primary_10_1053_j_semnuclmed_2008_12_001 crossref_primary_10_1007_s11888_008_0017_y crossref_primary_10_1586_14737140_8_11_1797 crossref_primary_10_1007_s00280_013_2145_6 crossref_primary_10_1038_sj_bjc_6605595 crossref_primary_10_1038_sj_bjc_6605114 crossref_primary_10_1159_000109957 crossref_primary_10_1038_bjp_2008_268 crossref_primary_10_1186_s12986_017_0180_8 crossref_primary_10_1590_s1679_45082011rw2220 crossref_primary_10_1016_j_ejso_2009_10_006 crossref_primary_10_3748_wjg_15_6091 crossref_primary_10_1007_s10637_010_9418_2 crossref_primary_10_1016_j_thorsurg_2005_11_003 crossref_primary_10_1093_annonc_mdm516 crossref_primary_10_1016_S1548_5315_11_70756_2 crossref_primary_10_1517_14656560903427997 crossref_primary_10_2478_raon_2019_0033 crossref_primary_10_1245_s10434_007_9607_1 crossref_primary_10_3233_CBM_160592 crossref_primary_10_1186_1471_2407_12_89 crossref_primary_10_1158_1078_0432_CCR_06_1250 crossref_primary_10_1586_14737140_6_5_785 crossref_primary_10_1245_s10434_014_4363_5 crossref_primary_10_1148_radiol_2473070949 crossref_primary_10_1634_theoncologist_11_9_1018 crossref_primary_10_1200_JCO_2006_08_1844 crossref_primary_10_1016_S0213_4853_10_70036_0 crossref_primary_10_1016_j_chembiol_2015_08_005 crossref_primary_10_1200_JCO_2007_12_1764 crossref_primary_10_1016_j_ejca_2009_08_011 crossref_primary_10_1002_ijc_22645 crossref_primary_10_1007_s12038_010_0064_9 crossref_primary_10_1634_theoncologist_11_9_981 crossref_primary_10_1016_j_jvir_2007_06_027 crossref_primary_10_1016_j_ctrv_2010_04_005 crossref_primary_10_1016_j_cpet_2016_05_004 crossref_primary_10_1016_j_phrs_2017_03_021 crossref_primary_10_1007_s10330_018_0321_1 crossref_primary_10_3389_fphar_2022_904909 crossref_primary_10_1002_jso_20926 crossref_primary_10_1517_13543776_16_2_189 crossref_primary_10_1007_s00432_008_0468_1 crossref_primary_10_1097_CAD_0b013e3283408596 crossref_primary_10_1007_s00280_009_1150_2 crossref_primary_10_1200_JCO_2006_06_1317 crossref_primary_10_3111_13696998_2011_650774 crossref_primary_10_1007_s12094_006_0058_0 crossref_primary_10_1158_0008_5472_CAN_06_0769 crossref_primary_10_1200_JOP_2010_000072 crossref_primary_10_1016_j_canlet_2011_06_026 crossref_primary_10_1177_030089160709300607 crossref_primary_10_2165_00063030_200721020_00001 crossref_primary_10_1016_S2173_5808_10_70022_5 crossref_primary_10_1016_j_asjsur_2020_12_028 |
Cites_doi | 10.1002/cncr.20594 10.1200/jco.2004.22.14_suppl.3514 10.1200/JCO.1987.5.10.1559 10.1056/NEJMoa032691 10.1016/S0140-6736(00)02034-1 10.1200/JCO.2003.10.066 10.1200/jco.2004.22.90140.3514 10.1200/jco.2004.22.90140.3621 10.1200/jco.2004.22.90140.3558 10.1200/JCO.1997.15.2.808 10.1093/annonc/mdh907 10.1200/jco.2004.22.90140.3690 10.1200/jco.2004.22.90140.3748 10.1016/S0959-8049(01)81446-5 10.1200/JCO.2001.19.9.2413 10.1007/s10434-001-0347-3 10.1200/JCO.2001.19.8.2282 10.1200/JCO.2004.09.046 10.1200/JCO.2001.19.18.3801 10.1200/JCO.1992.10.6.896 10.1200/JCO.1989.7.10.1419 10.1200/JCO.1994.12.1.14 10.1093/annonc/mdg360 10.1200/JCO.1989.7.10.1407 10.1200/jco.2004.22.90140.3580 10.1200/JCO.2003.11.122 10.1093/annonc/mdi092 10.1056/NEJM200009283431302 10.1200/JCO.2004.11.037 10.1200/JCO.1998.16.1.301 10.1200/jco.2004.22.14_suppl.3565 10.1200/jco.2004.22.90140.3602 10.1056/NEJMoa033025 10.1200/jco.2004.22.90140.3658 10.1200/jco.2004.22.90140.3571 10.1200/JCO.2002.07.087 10.1200/jco.2004.22.90140.3579 10.1200/jco.2004.22.14_suppl.2084 10.1200/JCO.2000.18.1.136 10.1093/annonc/mdg376 10.1200/JCO.2004.06.114 10.1136/bmj.321.7260.531 10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R 10.1016/S0959-8049(01)00415-4 10.1200/JCO.2003.09.016 10.1200/JCO.2000.18.16.2938 10.1200/JCO.2001.19.21.4097 10.1002/cncr.11910 10.1200/jco.2004.22.90140.3556 10.1093/annonc/mdi047 10.1200/JCO.2004.05.113 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1200/JCO.2005.17.749 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 4560 |
ExternalDocumentID | 10_1200_JCO_2005_17_749 16002847 jco23_20_4553 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | - 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 8WZ A6W AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADBIT ADKWQ AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AWKKM AZFZN BAWUL CS3 DIK EBS EJD F5P FD8 FH7 GJ GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 X7M YCJ ZA5 ZGI --- .55 .GJ 08P 0R~ 18M AAKAS AAYOK ABJNI ACGFO ACGUR ADZCM AEGXH AI. AIAGR C45 CGR CUY CVF ECM EIF F9R FBNNL HZ~ MJL N4W NPM QTD R1G RLZ TEORI TR2 VVN YFH YQY AAYXX CITATION |
ID | FETCH-LOGICAL-c393t-e85cfcaa992959ea2f92035d69419b06fb6097c7240aecf8159a47acb07288d13 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 03:02:08 EDT 2024 Sat Sep 28 07:44:40 EDT 2024 Tue Jan 05 20:17:05 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 20 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c393t-e85cfcaa992959ea2f92035d69419b06fb6097c7240aecf8159a47acb07288d13 |
PMID | 16002847 |
PageCount | 8 |
ParticipantIDs | crossref_primary_10_1200_JCO_2005_17_749 pubmed_primary_16002847 highwire_smallpub2_jco23_20_4553 |
ProviderPackageCode | RHI |
PublicationCentury | 2000 |
PublicationDate | 2005-07-10 |
PublicationDateYYYYMMDD | 2005-07-10 |
PublicationDate_xml | – month: 07 year: 2005 text: 2005-07-10 day: 10 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2005 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
References | BIB16 BIB17 BIB18 BIB19 BIB60 BIB62 BIB67 BIB24 BIB68 BIB25 BIB69 BIB26 BIB63 BIB20 BIB64 BIB21 BIB65 BIB22 BIB66 BIB9 BIB8 BIB7 BIB6 BIB5 BIB28 BIB4 BIB3 BIB2 BIB34 BIB35 BIB36 BIB37 BIB30 BIB31 BIB32 BIB33 BIB38 BIB39 BIB40 BIB45 BIB46 BIB47 BIB41 BIB42 BIB43 BIB44 BIB49 BIB50 BIB12 BIB56 BIB13 BIB57 BIB14 BIB58 BIB15 BIB59 BIB52 BIB10 BIB54 BIB11 |
References_xml | – ident: BIB36 doi: 10.1002/cncr.20594 – ident: BIB58 doi: 10.1200/jco.2004.22.14_suppl.3514 – ident: BIB47 – ident: BIB8 doi: 10.1200/JCO.1987.5.10.1559 – ident: BIB15 doi: 10.1056/NEJMoa032691 – ident: BIB11 doi: 10.1016/S0140-6736(00)02034-1 – ident: BIB16 doi: 10.1200/JCO.2003.10.066 – ident: BIB64 doi: 10.1200/jco.2004.22.90140.3514 – ident: BIB19 doi: 10.1200/jco.2004.22.90140.3621 – ident: BIB63 doi: 10.1200/jco.2004.22.90140.3558 – ident: BIB6 – ident: BIB21 doi: 10.1200/JCO.1997.15.2.808 – ident: BIB65 doi: 10.1093/annonc/mdh907 – ident: BIB56 doi: 10.1200/jco.2004.22.90140.3690 – ident: BIB66 doi: 10.1200/jco.2004.22.90140.3748 – ident: BIB14 doi: 10.1016/S0959-8049(01)81446-5 – ident: BIB7 doi: 10.1200/JCO.2001.19.9.2413 – ident: BIB69 doi: 10.1007/s10434-001-0347-3 – ident: BIB33 doi: 10.1200/JCO.2001.19.8.2282 – ident: BIB12 doi: 10.1200/JCO.2004.09.046 – ident: BIB26 doi: 10.1200/JCO.2001.19.18.3801 – ident: BIB46 – ident: BIB4 doi: 10.1200/JCO.1992.10.6.896 – ident: BIB3 doi: 10.1200/JCO.1989.7.10.1419 – ident: BIB24 doi: 10.1200/JCO.1994.12.1.14 – ident: BIB44 doi: 10.1093/annonc/mdg360 – ident: BIB2 doi: 10.1200/JCO.1989.7.10.1407 – ident: BIB68 doi: 10.1200/jco.2004.22.90140.3580 – ident: BIB22 doi: 10.1200/JCO.2003.11.122 – ident: BIB52 doi: 10.1093/annonc/mdi092 – ident: BIB10 doi: 10.1056/NEJM200009283431302 – ident: BIB28 doi: 10.1200/JCO.2004.11.037 – ident: BIB32 doi: 10.1200/JCO.1998.16.1.301 – ident: BIB30 doi: 10.1200/jco.2004.22.14_suppl.3565 – ident: BIB37 doi: 10.1200/jco.2004.22.90140.3602 – ident: BIB18 doi: 10.1056/NEJMoa033025 – ident: BIB40 doi: 10.1200/jco.2004.22.90140.3658 – ident: BIB31 doi: 10.1200/jco.2004.22.90140.3571 – ident: BIB45 doi: 10.1200/JCO.2002.07.087 – ident: BIB60 doi: 10.1200/jco.2004.22.14_suppl.3514 – ident: BIB67 doi: 10.1200/jco.2004.22.90140.3579 – ident: BIB54 – ident: BIB42 doi: 10.1200/jco.2004.22.14_suppl.2084 – ident: BIB25 doi: 10.1200/JCO.2000.18.1.136 – ident: BIB39 doi: 10.1093/annonc/mdg376 – ident: BIB50 doi: 10.1200/JCO.2004.06.114 – ident: BIB5 doi: 10.1136/bmj.321.7260.531 – ident: BIB9 doi: 10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R – ident: BIB34 doi: 10.1016/S0959-8049(01)00415-4 – ident: BIB43 doi: 10.1200/JCO.2003.09.016 – ident: BIB13 doi: 10.1200/JCO.2000.18.16.2938 – ident: BIB35 doi: 10.1200/JCO.2001.19.21.4097 – ident: BIB41 doi: 10.1002/cncr.11910 – ident: BIB62 doi: 10.1200/jco.2004.22.90140.3556 – ident: BIB38 doi: 10.1093/annonc/mdi047 – ident: BIB59 – ident: BIB20 doi: 10.1200/JCO.2004.05.113 – ident: BIB17 – ident: BIB49 doi: 10.1200/JCO.2004.06.114 – ident: BIB57 doi: 10.1200/jco.2004.22.14_suppl.3565 |
SSID | ssj0014835 |
Score | 2.3735802 |
SecondaryResourceType | review_article |
Snippet | Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival over fluorouracil with... |
SourceID | crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 4553 |
SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Trials as Topic Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Drug Administration Schedule Humans Survival Rate |
Title | Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence |
URI | http://jco.ascopubs.org/content/23/20/4553.abstract https://www.ncbi.nlm.nih.gov/pubmed/16002847 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZdC2MvZetu2Q09lDJYnNnyRXLfSrY2W8nShxTyZiRZho3MKav3kP36HflI9hJaaPcQE4QjJzpfjj5J53yHkMOszCpdGRHIyFRBokoeAKmPg4gZnXFuMq1tcvL0Wza5TL4u0kUfkNlmlzRqpP_cmFfyP1aFNrCrzZK9h2W7TqEB3oN94QoWhuudbIxy49-1jZuw2gBtzODUNNKmCUHzGDyb9Wh2g8Baty0J6RWZZhjOgrqa2ORLjN7CWLssylWtN3bjz40rWD2Rdd35-bPVsvTRYy5__8N0tLHNkNr9Sxdwit6IxyyA__8CJw7nLRkHeo46u96dYvqwgw0L_3GOSYq6wG6iBeoW3ujEGdanHs9wyyviI46yppty2VvTWBdcaJc1zJ7RjWe2yGZaRLyADh6QPcbz1C7QP305706aEoFFWP3Pc_JP8MGPW99gk7l4Nemt5UhLS-aPyb6zDj1BcDwhO6Y-IA-nLmLigBxdoDb5ekjnfard9ZAe0YtetXz9lMw9mNx9awpgoj2YaA8mimA6pg431EFp2DV4ID0jl6ef5-NJ4EpuBDrO4yYwItWVljIH1pzmRrIqZ2GcljbdOVdhVqkszLnmwAOl0ZUAMiwTLrUKOROijOLnZLde1eYloSKTGvhpGRnFEngJVoZclypWRgqp2IC898NZXKGySnGL6QaE-uEurn_K5RJGnBU_9IrFcFthcTUgL9AMfV_2xBm416u7P-c1edRD_w3ZbX79Nm-BczbqXQuavydRftA |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systemic+Therapy+for+Metastatic+Colorectal+Cancer%3A+Current+Options%2C+Current+Evidence&rft.jtitle=Journal+of+clinical+oncology&rft.au=Kelly%2C+Hanna&rft.au=Goldberg%2C+Richard+M.&rft.date=2005-07-10&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=23&rft.issue=20&rft.spage=4553&rft.epage=4560&rft_id=info:doi/10.1200%2FJCO.2005.17.749&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_JCO_2005_17_749 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |